Aldeyra Therapeutics (ALDX) Interest & Investment Income (2013 - 2026)
Aldeyra Therapeutics (ALDX) posted Interest & Investment Income of $562977.0 for Q1 2026, down 17.41% on a QoQ basis from $681635.0 in Q4 2025, and down 42.64% year-over-year from $981487.0 in Q1 2025.
Aldeyra Therapeutics (ALDX) Interest & Investment Income (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics' Interest & Investment Income history runs 13 years deep, the most recent figure standing at $562977.0 for Q1 2026.
- Quarterly Interest & Investment Income fell 42.64% year-over-year to $562977.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (down 45.83% YoY) and the FY2025 annual result came in at $3.3 million, down 46.32% from the prior year.
- Interest & Investment Income was $562977.0 for Q1 2026 at Aldeyra Therapeutics, down from $681635.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $1.9 million in Q3 2023 and bottomed at $101382.0 in Q1 2022.
- A 5-year average of $1.2 million and a median of $1.2 million in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income surged 1904.52% — and 2025, when it sank 47.55%.
- Aldeyra Therapeutics' Interest & Investment Income stood at $1.3 million in 2022, then surged by 48.08% to $1.9 million in 2023, then tumbled by 33.31% to $1.2 million in 2024, then sank by 45.02% to $681635.0 in 2025, then retreated by 17.41% to $562977.0 in 2026.
- Business Quant data shows ALDX's Interest & Investment Income at $562977.0 in Q1 2026, $681635.0 in Q4 2025, and $788694.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Aldeyra Therapeutics | 95.00 Mn | 95.00 Mn | - | 562,977.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 562,977.00 |
| Dec 31, 2025 | 681,635.00 |
| Sep 30, 2025 | 788,694.00 |
| Jun 30, 2025 | 872,038.00 |
| Mar 31, 2025 | 981,487.00 |
| Dec 31, 2024 | 1.24 Mn |
| Sep 30, 2024 | 1.50 Mn |
| Jun 30, 2024 | 1.64 Mn |
| Mar 31, 2024 | 1.81 Mn |
| Dec 31, 2023 | 1.86 Mn |
| Sep 30, 2023 | 1.90 Mn |
| Jun 30, 2023 | 1.88 Mn |
| Mar 31, 2023 | 1.68 Mn |
| Dec 31, 2022 | 1.26 Mn |
| Sep 30, 2022 | 648,242.00 |
| Jun 30, 2022 | 344,378.00 |
| Mar 31, 2022 | 101,382.00 |
| Dec 31, 2021 | 62,631.00 |
| Sep 30, 2021 | 59,306.00 |
| Jun 30, 2021 | 39,665.00 |